

## Genetics Report


**Patient details:**

**Sample details:**

**Clinical Summary:** CML on imatinib for 18 months. For *BCR-ABL1* monitoring by RT-qPCR.

### *BCR-ABL1* quantitative PCR (RT-qPCR) monitoring report (transcript type = e13a2/e14a2)

Treatment response	<i>BCR-ABL1:ABL1</i> % ratio on IS	MR level	Date next sample due
Optimal	Undetectable	MR <sup>4.5</sup>	May 2018



Reported by:

Authorised by:

Laboratory Number (Sample Type)	Date received	Copies of <i>BCR-ABL1</i>	Copies of <i>ABL1</i>	<i>BCR-ABL1:ABL1</i> ratio (IS)	<i>BCR-ABL1:ABL1</i> ratio on IS (%)	Sensitivity of detection (1/ <i>ABL1</i> )	Molecular Response (MR)
	23/06/2016	360,000	137,000	3.664	366.35	0.000007	
	04/10/2016	31,000	79,000	0.543	54.32	0.000013	#NA
	06/12/2016	1,500	41,000	0.052	5.22	0.000025	MR <sup>1</sup>
	19/04/2017	15	96,000	0.0002	0.023	0.000010	MR <sup>3</sup>
	26/07/2017	0	146,000			0.000007	MR <sup>5</sup>
	15/11/2017	0	82,000			0.000012	MR <sup>4.5</sup>